Leerink Partners Maintains a Buy on Madrigal Pharmaceuticals (MDGL), Here's Why

Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) is one of the Best Mid Cap Growth Stocks to Buy According to Hedge Funds. On August 19, Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) announced receiving a conditional marketing authorization for Rezdiffra from the European Commission. Rezdiffra treats adults with noncirrhotic MASH and moderate to advanced liver fibrosis. Wall Street has been bullish on the stock, and the stock has surged more than 8.5% since the announcement.

Recently, on August 20, Leerink Partners analyst Thomas Smith maintained a Buy rating on Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) without disclosing any price target. The analyst noted that the approval is important because it allows treatment for noncirrhotic MASH without needing a biopsy. Moreover, Rezdiffra is now the first and only therapy approved for MASH in Europe and also fits well with the European treatment guidelines.

Management also plans to start selling the treatment in Germany and then expand across Europe.

Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) is a biotechnology company that develops treatments for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease.

While we acknowledge the potential of MDGL as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.